Efek N-Asetil-L- Sistein (NAC) Terhadap Kadar Adma Plasma Dan Ekspresi Protein Vcam-l Pada Disfungsi Endotel Tikus Diabetes by Santi, I. (Irma) et al.
Efek N-Asetil-L- Sistein (NAC) terhadap Penurunan Kadar Adma Plasma ... (Irma Santi, Budi Suprapti, Imam Susilo dan Junaidi Khotib )
147
Efek N-Asetil-L- Sistein (NAC) terhadap Kadar Adma Plasma dan Ekspresi 
Protein Vcam-l pada Disfungsi Endotel Tikus Diabetes
THE EFFECT OF N-ACETYL-L-CYSTEINE (NAC) ON PLASMA ADMA LEVEL AND THE 
EXPRESSION OF VCAM-1 PROTEIN ON ENDOTELIAL DYSFUNCTION IN DIABETIC RATS
Irma Santi, Budi Suprapti, Imam Susilo dan Junaidi Khotib
Program Magister Ilmu Farmasi, Fakultas Farmasi Universitas Airlangga
Kampus B Unair JI. Dharmawangsa Dalam Surabaya 60286, lndonesia
Email: irma.santi@umi.ac.id
         Submitted : 4-3-2016,   Revised : 4-3-2016,    Revised : 1-6-2016,    Accepted : 24-6-2016
Abstract
Endothelial dysfunction is an early state of symptoms in a cardiovascular disease. An elevated 
oxidative stress plays a key role in the pathogenesis of macrovascular diabetic complication. The 
present study was design to evaluate the effect of NAC on plasma ADMA level and the expression of 
VCAM-1 protein on endothelial dysfunction in diabetic rats. Thirty male Sprague–Dawley rats were 
divided into 5 groups i.e. normal rats, diabetic rats, treatment with NAC 30 mg/kgBW, NAC 56 mg/
kgBW and NAC 100 mg/kgBW. Diabetic rats model was induced by intraperitonial administration of 
alloxan monohydrate  at dose of 150 mg/kgBW, diabetes occurred on 3nd  day after alloxan injection 
and then started treatment of  N-acetyl-L-cystein  for 28 days.  ADMA plasma level was analyzed 
with Elisa Reader and the expression of VCAM-1 protein was evaluated by immunohistochemistry. 
Conclusion of this research is that treatment with NAC 30 mg/kgBW, NAC 56 mg/kgBW and NAC 
100 mg/kgBW for 28 days may prevent oxidative stress indicated by the decreasing of plasma ADMA 
level by 45.8%:  55.75% and 65.92%, respectively and the decreasing of  the expression of VCAM-1 
protein on endothelial dysfunction in diabetic  rat by 24%: 31.75% and 58.92%, respectively.
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Abstrak
Disfungsi endotel merupakan tahap awal pada penyakit kardiovaskular. Peningkatan stres oksidatif 
berperan penting dalam patogenesis komplikasi makrovaskular pada penyakit diabetes. Penelitian 
ini bertujuan untuk mengevaluasi efek N-asetil sistein (NAC)  dalam menurunkan kadar ADMA 
plasma dan ekspresi protein VCAM-1 pada disfungsi endotel tikus diabetes. 30 tikus jantan strain 
sprague- Dawley dibagi menjadi 5 kelompok yaitu kelompok normal, kelompok diabetes,  kelompok 
perlakuan NAC pada dosis 30, 56 dan 100 mg/kgBB. Model tikus diabetes diperoleh dengan 
diinduksi  aloksan monohidrat 150 mg/kgBB secara intraperitonial, kondisi diabetes terjadi pada 
hari ke-3 setelah induksi aloksan selanjutnya dilakukan pemberian N-asetil sistein selama 28 hari. 
Kadar ADMA plasma dianalisis dengan metode  ELISA  dan ekspresi  protein VCAM-1 dianalisis 
secara imunohistokimia. Kesimpulan dari penelitian ini bahwa pemberian NAC pada dosis 30, 56 
dan 100 mg/kgBB selama 28 hari dapat mencegah peningkatan stres oksidatif yang ditandai dengan 
menurunnya kadar ADMA plasma berturut-turut  45,80%; 55,75% dan 65,92% serta menurunnya 
ekspresi dari protein VCAM-1 pada disfungsi endotel tikus diabetes berturut-turut 24,00% ;31,75% 
dan 58,92%.
Kata kunci : ADMA, Endothelial dysfunction, NAC, VCAM-1
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INTRODUCTION
 Diabetes mellitus (DM)  is a chronic 
disease characterized by elevated blood sugar levels 
resulting from either a lack of insulin production or 
resistence to insulin.1 WHO estimated that in 2030 
prevalence of  DM in Indonesia will be increasing 
by 21,3 million people.2 The global figure of people 
with diabetes is projected to increase to 333 million 
in 2025 and 430 million in 2030.1
 Diabetic Mellitus sufferers have 
many chance getting complications including 
macrovascular complications (CVD), such as 
atheroclerosis, stroke and  myocardial infarction. 
CVD accounts for more than half of the mortality 
seen in the diabetic population and diabetes equates 
to an approximately threefold increased risk of 
myocardial infarction compared with the general 
population.3,4
 Endothelial dysfunction is an early state of 
symptoms in cardiovascular disease. Endothelial 
dysfunction are characterized by alteration of 
homeostasis endothelium of the antihemostatic 
properties, vascular tone, increase of  leukocyte 
adhesion and production of cytokines and growth 
factors.5 Endothelium-derived nitric oxide (NO) is 
formed in the endothelium by the endothelial isoform 
of nitric oxide synthase (eNOS), NO is a potent 
endogenous vasodilator mediators play a crucial 
role in vascular homeostasis. A reduction in NO can 
result in endothelial dysfunction and in an increased 
risk for cardiovascular disease.6 An elevated 
oxidative stress plays a key role in the pathogenesis 
of macrovascular diabetic complication.1
 The most important mechanism involved 
in the complex series of reaction associated 
with accelerated atherosclerosis indiabetes is the 
increase in the irreversible formation and deposition 
of reactive advanced glycation endproducts 
(AGEs). The intermolecular collagen cross-linking 
caused by AGEs leads to diminished arterial and 
myocardial compliance and increased vascular 
stiffness, phenomena that are considered to partly 
explain the increase in diastolic dysfunction and 
systolic hypertension seen in diabetic subjects.7 
AGE interaction with receptor of advanced 
glycation endproducts (RAGE) is the induction 
of oxidative stress, leading to NF-ĸB activation 
and the induction of the endothelial expression of 
various cell adhesion molecules, including vascular 
cell adhesion molecule-1 (VCAM-1). Endothelial 
dysfunction is indicated by the expression of 
VCAM-1 protein, increasing of VCAM-1 expression 
promotes transendothelial migration of monocytes, 
thereby contributing  to the formation of foam cells 
and initiation of atherosclerosis formation.5
 Futhermore, reactive oxygen species 
(ROS), which oxidize lipids, proteins and DNA 
causing cellular damage and subsequent cell 
death.8 One of protein which oxidized is indicated 
by the increasing of plasma asymmetrical 
dimethylarginine (ADMA) level. Increasing of 
ADMA level caused by increasing of regulation 
protein arginine methyltransferase (PRMT) 
expression and decreasing of dimethylarginine 
dimethylaminohydrolase (DDAH) activity. ADMA 
is a naturally occurring endogenous inhibitor of 
nitric oxide (NO) synthase. ADMA inhibits eNOS 
by competitive displacement of the physilogical 
substrate, L-arginine, from the enzyme.9 ADMA 
reduces NO production and consequently could thus 
lead to endothelial dysfunction and development to 
cardiovascular events.6,9
 An elevated oxidative stress that induce to 
increase of plasma ADMA level and the expression 
of VCAM-1 protein caused by imbalance between 
the increasing of reactive oxygen spesies (ROS) 
and decreasing of endogen antioxidant capacity in 
cell, particularly decreasing of endogen glutation 
antioxidant (GSH).
 Endogen gluthation antioxidant can be 
increased by using NAC. NAC is precursor cystein 
and GSH.10 NAC deacetylation become cystein, then 
cystein involve glutation metabolism pathway and 
increase intraceluler glutation Formation.11 NAC 
is a source of sulfhydryl (-SH) as act antioxidant 
group in cells and scavenger  of free radicals  in 
direct such as superoxide (O2•-) hydrogen peroxide 
(H2O2) and hydroxyl (OH•).12
 The aims  of this research are  to determine 
the effect of N-acetyl-L-cysteine  to decrease ADMA 
level and the expression of VCAM-1 protein that is 
marker of endothelial dysfunction in diabetic rats.
 The advantage of this research is to give 
the scientific information of the role of NAC as 
antioxidant on endothelial dysfunction in the 
prevention  the development of  macrovascular 
diabetic complication in diabetic state.
MATERIALS AND METHODS
 The present study was conducted by 
using the postest-only control group design.13 
The treatment of animals  in this experiment  was 
approved by Airlangga University Animal Care and 
Use Committee (ACUC), Surabaya, Indonesia.
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Materials
 N-acetyl-L-cyste ine(NAC)(Sigma-
Aldrich, USA), alloxan monohydrate (Sigma-
Aldrich, USA), Antibody VCAM-1, sc-1504 
(Santa Cruz Biotechnology,USA) and kit for 
immunohistochemistry (Biocare Medical, USA). 
ADMA Elisa Kit (Elabscience) and other reagens, 
such as  formaldehyde, PBS, and aquadest (PT. 
Bratachem Ltd,Surabaya, Indonesia).
Animals
 Thirty male rats of Sprague–Dawley 
strain, weighing between 180 – 250 g, two 
month age, blood glucose < 200 mg/dl. Animals 
were maintained in the climatically  controlled 
housing facility  in Animal Laboratory, Faculty 
of Pharmacy, Airlangga University, Indonesia for 
a week before the initiation of the experiment.
Experimental Protocol
 Rats were divided into five groups. Rats 
in naive group received buffer citrat 0.1 M pH 4.5 
diabetic rats model was induced by intraperitonial 
administration of alloxan monohydrate at dose 
150 mg/kgBW,  diabetes occurred on 3rd day after 
alloxan injection. Both the naive and diabetic groups 
receive drinking water, whereas the treatment groups 
received NAC in different dose i.e 30 mg/kgBW, 56 
mg/kgBW, and 100 mg/kgBW p.o. Both NAC or 
drinking water administered everyday for 28 days. 
During the treatment, blood glucose level of naive 
and diabetic groups were observed with glucometer 
on day 14 and 28. On 29th day, all of rats were 
sacrificed then the plasma were collected for  plasma 
ADMA level data and the aortic tissue section are 
also collected and prepared by imunohistochemestry 
method for measuring the expression of VCAM-1 
protein. Rats were sacrificed  and were taken blood 
and  its aortic tissue then was put into a plastic bag 
and wrapped with paper, covered and stored in the 
refrigerator or directly be burnt.
Determination of blood glucose levels 
 Blood samples were taken from the tail vein 
of  rat for determination of blood glucose level using 
one call plus glucometer® 
Plasma ADMA level  assay
 Plasma levels of ADMA were determined 
by an ELISA kit.9 It uses Competitive-ELISA as 
the method. The mechanism of this method is based 
on the interaction between antibody and antigen in 
sample which using enzym as label reporter.14
Immunohistochemistry and VCAM-1 expression 
scoring
 Aortic tissues were collected and fixated 
in 10% neutral buffered formalin for 24 h at room 
temperature. The tissues were then embedded 
in paraffin wax and sections were cut at 4 µm 
thickness and stained with rat antibody VCAM-1, 
for overnight incubation at 40°C. Then, VCAM-
1 expression was observed on the endothelial cell 
surface and calculated using Allred scoring system 
by combining the percentage of positive cells and 
intensity of the reaction product in most of the 
examined field.15
Statistical analysis 
 The results are expressed as means ± 
standard deviation (x± SD) for plasma ADMA 
level and VCAM-1 data. Comparison between the 
groups were performed by using one-way analysis 
of variance (ANOVA), continued with Tukey's 
procedure for multiple comparison tests in order to 
obtain plasma ADMA level data. However, scoring 
of VCAM-1 expression were analyzed with Mann 
Whitney test. A value of p < 0.05 was considered to 
be significant.
RESULT
1. The effect alloxan monohidrate of blood 
glucose level in diabetic rat model.
 As illustrated in Table 1, diabetic model was 
induced by  alloxan monohidrate 150 mg/kgBB, 
shown by significantly increased in blood glucose 
level (p<0.001).
Table 1. Increasing of blood glucose level in diabetic state after induction of alloxan  monohidrate at dose 
              150 mg/kgBB
Group                       Blood glucose level (mg/dl) x±  SD
0 3 14 28
Naive      108.7 ± 11.8       107.7 ± 13.8      107.8 ± 16.1   109.2 ± 20.4
DM      109.7 ± 10.6       > 600.0 ± 0.0      > 600.0 ± 0.0   594.7 ± 10.8***
***) significant differences (p< 0,001) vs naive group
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2. The effect  NAC to decrease plasma ADMA 
level in diabetic rat model
 As illustrated in Fig. 1,  in diabetic 
condition, elevated oxidative stress as shown by 
significant increasing in plasma ADMA level from 
1.05 ± 0.03 to 3.58 ± 0.12 . As illusrated in Fig 
2, NAC administration  at different doses (30, 56, 
and 100 mg/kg BW)  decreased plasma ADMA 
level by 45.8%: 55.75%, and 65.92%, respectively 
(p<0.001).
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Figure 1. Plasma ADMA level after induction of all-
    oxan monohidrate at dose 150  mg/kgBB
 
Figure 2. Plasma ADMA level after NAC adminis-
                 tration for 28 days
3. The effect  NAC to decrease the expression of 
VCAM-1 protein on endothelial dysfunction in 
diabetic rat model
 As illustrated in Fig. 3 and Table 2, staining 
with rat antibody VCAM-1 sc-1504 (1:100), on 
the expression of VCAM-1 proteinon endothelial 
cell surface was conducted, as shown in Fig.3, 
negative staining was shown in aortic tissue 
from naive group, as shown in panel A, positive 
staining was shown in dark brown (Red arrow) on 
endothelial cell surface in all groups induced by 
alloxan. The strongest expression was observed 
in diabetic untreated group, as shown in panel B 
significantly increasing from 1.87 ± 0.20 to 6.33 
± 0.55. As illustrated in Fig. 4 and Table 3, the 
expression of VCAM-1 protein on EC surface 
decreased gradually after NAC administration for 
28 days, as illustrated in panel C (NAC 30 mg/kg 
BW), D (NAC 56 mg/kg BW), and panel E (NAC 
100 mg/kg BW). The Scoring for the expression 
of VCAM-1 protein was determined by Allred 
scoring system (data was not shown). And was 
analyzed with Mann Whitney test showed NAC 
administration in the treatment group (30, 56, 
and 100 mg/kgBW) significantly decreasing the 
expression of VCAM-1 protein by 24%: 31.75% 
and 58.92%, respectively (p= 0.001).
Figure 3. Expression of  VCAM-1 protein  in endothelial surface by staining antibody VCAM-1 (1:100), 
                shown in dark brown (Red arrow). Naive group, shown in panel A (400x) and DM group in 
                panel B (400x).
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Table 2.  Score expression of VCAM-1 Protein
Group Score expression of VCAM-1 protein (x± SD) 
Naïve 1.87 ± 0.20
DM 6.33  ± 0.55*
*) Significant differences (p=0.003) vs naive group
Figure 4. Expression  of VCAM-1 protein in endothelial surface by staining antibody VCAM-1 (1:100), 400x. 
                   shown in dark brown (red arrow) (B) DM group(C) DM+NAC 30 mg/kg BW, (D) DM+NAC 56 mg/
                kg BW, and (E) DM +NAC 100 mg/kgBW
Table 3. Score expression of VCAM-1 protein after NAC administration for 28 days
Group Score expression of VCAM-1 protein (x± SD)
DM 6.33  ±  0.55
DM + NAC 30 4.80  ±  0.99
DM + NAC 56 4.32  ±  0.41
DM + NAC 100 2.60 ±   0.24 
DISCUSSION
 Diabetes is an important and independent 
risk factor for the development of cardiovascular 
complications and obstructive vascular diseases 
involving several body systems. Being the 
distinguishing feature of diabetes, hyperglycemia 
has been suggested  to play a key role, via oxidative 
stress, inmediation of these complications.16
 Endothelial function is important for 
the homeostasis of the body and its dysfunction 
is associated with several pathophysiological 
conditions, including atherosclerosis, hypertension 
and diabetes. Understanding and treating endothelial 
dysfunction is a major issue in the prevention of 
vascular complications associated with all forms of 
diabetes mellitus.17
 The key role played by reactive oxygen 
species in the mediation of the vascular complications 
of diabetes is also reinforced by studies showing 
that antioxidants such as vitamin E, superoxide 
dismutase, catalase,  ascorbic acid and glutathione 
(GSH) are all decreased in blood and tissue of diabetic 
animals. This decrease in endogenously occurring 
antioxidants will also result in increased oxidative 
injury by failure of protective mechanisms.16
 An elevated oxidative stress can be reduced 
by using NAC. NAC is precursor cystein and GSH.10 
NAC deacetylation become cystein, then cystein 
involve in glutation metabolism pathway and 
increase intraceluler glutation  formation. NAC is a 
source of sulfhydryl (-SH) as act antioxidant  group 
in cells and scavenger  of free radicals  in direct such 
as superoxide (O2•-) hydrogen peroxide (H2O2) and 
hydroxyl (OH•).12
 This study used male sprague – dawley (SD) 
rat induced by intraperitoneally alloxan monohidrate 
150 mg/kgBB,an intraperitoneal dose below 150 
mg/kg may be insufficient for inducing diabetes in 
this animal species.18 Alloxan and the product of its 
reduction, dialuric acid, establish a redox cycle with 
the formation of superoxide radicals. These radicals 
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undergo dismutation to hydrogen peroxide with a 
simultaneous massive increase in cytosolic calcium 
concentration, which causes rapid destruction of 
pancreatic β-cells.19
 Increasing of plasma ADMA level and 
expression of VCAM-1 protein that marker of 
oxidative stress are consequently could thus lead 
to endothelial dysfunction and development to 
cardiovascular events.6
 Increasing of endogen antioxidant capacity 
in cell, particularly increasing of endogen glutation 
antioxidant (GSH) by NAC  causes  a decrease in 
markers of oxidative stress that plasma ADMA 
level  and expression of VCAM-1 protein. So that 
prevention of vascular complications associated 
with all forms of diabetes mellitus.
CONCLUSION
 Our data show that the treatment with NAC 
as an antioxidant can reduce plasma ADMA level and 
the expression of protein VCAM-1 on endothelial 
cell dysfunction in  diabetic rat model indicate in 
the  prevention  the development of macrovascular 
diabetic complication. 
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